Renalyx Health Systems, a Bengaluru-based medtech innovator, has unveiled plans to invest Rs. 800 crore over the next four years to establish three state-of-the-art manufacturing facilities. The initiative aims to produce the RENALYX RxT 21, the world’s first fully indigenous AI- and cloud-enabled dialysis machine. With approvals from regulatory bodies such as CDSCO and EU CE, and FDA clearance in the pipeline, Renalyx is poised to revolutionize renal care in India and abroad.